NBIX
Neurocrine Biosciences Inc
138.40$
-0.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +95.4% | -23.1% | +123.9% | +21.5% | +31.5% | +32.8% | +19.5% | +14.3% | +37.3% | +14.4% | +24.5% | |
| – | +93.8% | -19.2% | +78.8% | +33.0% | +12.6% | +22.3% | -4.3% | +49.4% | +10.6% | +7.3% | +46.3% | |
| – | +139.2% | +12.2% | +205.9% | -44.4% | -20.8% | +66.6% | +82.1% | -22.9% | -4.5% | -7.2% | +206.0% | |
| – | +95.7% | -18.9% | +67.9% | +26.2% | +3.0% | +19.5% | -11.2% | +39.1% | +4.3% | +4.3% | +37.6% | |
| – | – | – | – | +80.7% | +125.1% | +24.1% | +18.1% | +88.7% | +25.5% | +9.1% | +43.4% | |
| – | – | – | – | – | +59.1% | +62.0% | +8.9% | +15.1% | +9.1% | +49.9% | +20.2% | |
| – | +36.9% | +82.7% | +72.4% | +213.3% | +23.8% | +6.4% | +31.4% | +0.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | +7.4% | -1.7% | – | |
| – | – | – | – | – | +11.7% | – | – | – | -4.6% | +2.8% | – | |
| – | +46.6% | -0.2% | +787.2% | +15.0% | +30.6% | -9.1% | +14.8% | -5.4% | +54.2% | +10.8% | +22.1% | |
| – | +64.2% | +18.3% | +79.0% | +62.1% | +540.7% | -67.0% | +31.8% | +118.8% | +21.8% | -22.5% | +46.4% | |
| – | – | +18.9% | +158.2% | +62.5% | +555.7% | -97.5% | +60.2% | +926.7% | +0.4% | – | – | |
| – | +941.1% | +98.6% | +11.1% | +144.4% | +234.9% | -14.7% | +30.7% | +30.7% | +98.1% | -25.1% | +5.0% | |
| – | – | – | – | +5.1% | +5.2% | -22.2% | +5.4% | – | – | – | – | |
| – | +103.4% | -25.8% | +18.2% | +29.2% | +32.5% | +76.8% | +22.0% | +24.3% | +30.7% | +16.0% | +25.6% | |
| – | – | – | – | – | – | – | – | – | – | – | +1,433.2% | |
| – | +13.3% | +2.6% | +1.6% | +8.3% | +0.3% | +2.2% | +0.1% | +1.0% | +2.1% | +2.7% | -1.2% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.